FindTrial
Sign In

The benefits of nalbuphine used in the painless delivery: a randomized controlled trial.

The benefits of nalbuphine used in the painless delivery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033221
Enrollment
Unknown
Registered
2020-05-24
Start date
2020-05-20
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless delivery

Interventions

Group 1:epidural (0.1%lopivacain+2ug/ml fentanyl)
Group 2:spinal 30ug fentanyl+epidural (0.1%lopivacain+2ug/ml fentanyl)
Group 3:spinal (30ug fentanyl+0.4mg nalbuphine)+epidural (0.1%lopivacain+2ug/ml fentanyl)

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Parturients aged 22 -35 years; (2) ASA I-II.

Exclusion criteria

Exclusion criteria: (1) be allergic to nalbuphine; (2) BMI > 35 kg/m2; (3) suffer from gestational hypertension; (4) AST, ALT > 1.5* normal high value or GFR 38 degrees C or < 36.5 degrees C; (7) coagulation dysfunction.

Design outcomes

Primary

MeasureTime frame
VAS;motor block score;—

Secondary

MeasureTime frame
motor block score, the incidence of prutitus, shiver score, parturient satisfaction degree, delivery mode, Apgar score;—

Countries

China

Contacts

Public ContactYong Li

Ningbo First Hospital

yongli332603@163.com+86 15168541165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026